



Results of 2026 Annual General Meeting

23 October 2026

LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") is pleased to advise that shareholders of the Company passed all Resolutions by poll at the Annual General Meeting held today at 2:00pm (AEST).

In accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act, enclosed is a summary of the resolutions considered, the proxies received and the outcomes of voting for each respective resolution at the 2026 Annual General Meeting.

With regard to Resolution 1 - Adoption of Remuneration Report, the Resolution was passed with more than 75% votes in favour of the resolution.

- ENDS -

This announcement has been approved by the Company Secretary.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company developing and commercialising innovative therapies to address significant unmet medical needs. The Company's lead programs utilise its proprietary intranasal technology platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, **SPONTAN®** and **ROXUS®**, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing **OROFLOW®**, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

For more information on Marius Pharmaceuticals, visit: www.mariuspharma.com.

LTR Pharma Investor Centre

Stay informed with LTR Pharma's latest announcements and market updates by visiting our [Investor Centre](#) or scan the QR code.





LTR Pharma

For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com

Results of Meeting

LTR Pharma Limited

LTR Pharma Limited - Annual General Meeting

Friday, 23 October 2026



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
		FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	14,972,905 72.50%	3,097,488 15.00%	51,068	2,580,774 12.50%	15,110,679 82.99%	3,097,488 17.01%	51,068	-
2 Re-election of Lee Rodne as Director	P	71,346,895 96.40%	87,335 0.12%	220,820	2,580,774 3.49%	73,927,669 99.88%	87,335 0.12%	220,820	Carried
3 ASX Listing Rule 7.1A Approval of Future Issue of Securities (Additional 10% Placement Capacity)	P	68,526,042 92.31%	3,078,658 4.15%	0	2,631,124 3.54%	71,157,166 95.85%	3,078,658 4.15%	0	Carried
4 Readoption of Employee Incentive Plan	P	13,773,799 69.19%	3,501,218 17.59%	96,894	2,632,324 13.22%	13,963,123 79.95%	3,501,218 20.05%	96,894	Carried
5 Approval of Issue of Options to Lee Rodne, Director of the Company	P	14,747,634 68.42%	4,174,832 19.37%	7,500	2,632,324 12.21%	14,936,958 78.16%	4,174,832 21.84%	7,500	Carried
6 Approval of Issue of Options to Julian Chick, Director of the Company	P	67,190,521 91.60%	3,525,919 4.81%	78,568	2,632,324 3.59%	69,822,845 95.19%	3,525,919 4.81%	78,568	Carried
7 Approval of Issue of Options to Maja McGuire, Director of the Company	P	67,947,450 91.69%	3,525,919 4.76%	78,568	2,632,324 3.55%	70,579,774 95.24%	3,525,919 4.76%	78,568	Carried
8 Renewal of Proportional Takeover Provisions	P	68,913,645 92.85%	2,487,449 3.35%	12,261	2,822,469 3.80%	71,736,114 96.65%	2,487,449 3.35%	12,261	Carried

